title: Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration.
abstract: BACKGROUND
  This study measured skin hydration and occlusivity of two test products [halobetasol propionate lotion, 0.05% (HBP Lotion) and Ultravate® (halobetasol propionate) cream, 0.05% (HBP Cream)] at 2, 4, and 6 hours after application to skin test sites previously challenged by dry shaving, which was performed to compromise the integrity of the stratum corneum barrier.
  
  
  METHODS
  Trans-epidermal water loss (TEWL), an indicator of skin barrier function, was measured using cyberDERM, inc. RG-1 evaporimeter. Skin hydration was evaluated using IBS SkiCon-200 conductance meter. Test products were applied bilaterally on dry-shaved sites on the volar forearm sites, according to a randomization scheme, with two test sites untreated to serve as "dry-shaved" controls. TEWL and conductance were measured at 2, 4, and 6 hours post-treatment.
  
  
  RESULTS
  HBP Lotion displayed a significant increase in skin hydration at 2, 4, and 6 hours post-treatment compared to the baseline values and dry-shaved controls (each, P less than 0.001). However, HBP Cream produced statistically significant increased skin hydration only after 6 hours (P less than 0.05). HBP Lotion was significantly more effective than HBP Cream in increasing skin hydration at 2 and 4 hours post-treatment (each, P less than 0.001), and had a directional advantage (not statistically significant) at 6 hours. Neither test product had a significant occlusive effect as measured by TEWL at 2, 4, and 6 hours post-application.
  
  
  CONCLUSIONS
  Both formulations of HBP (Lotion and Cream) contributed to skin moisturization, as measured by skin conductance. HBP Lotion produced a significantly more rapid onset and higher level of moisturization at 2 and 4 hours post-application compared to HBP Cream. The TEWL results indicate that neither HBP Lotion nor HBP Cream provided any significant occlusivity to the skin. <p><em>J Drugs Dermatol. 2017;16(2):140-144.</em></p>.
authors.forename: Gary
authors.initials: G
authors.lastname: Grove
authors.forename: Charles
authors.initials: C
authors.lastname: Zerweck
authors.forename: Tim
authors.initials: T
authors.lastname: Houser
authors.forename: Anthony
authors.initials: A
authors.lastname: Andrasfay
authors.forename: Bob
authors.initials: B
authors.lastname: Gauthier
authors.forename: Charles
authors.initials: C
authors.lastname: Holland
authors.forename: Daniel
authors.initials: D
authors.lastname: Piacquadio
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D002990:Clobetasol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004339:Drug Compounding; D004643:Emollients / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005542:Forearm; D006801:Humans; D008297:Male; D008875:Middle Aged; D063465:Skin Cream; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D014870:Water Loss, Insensible / Q000187:drug effects; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; D004643:Emollients; D014662:Vasoconstrictor Agents; C064466:halobetasol; D002990:Clobetasol